Endorsed – New method for evaluating severity of Alzheimer’s
Dementia ResearcherThe IMI AMYPAD project robustly assessed a numerical scale from 0-100 that can be used to quantitatively compare brain scans of Alzheimer’s patients.
Research News
GLP-1 Drug Liraglutide May Protect Against Dementia
Alzheimer's AssociationResearch reported at AAIC shows a GLP-1 agonist — the class of drugs shown to help with diabetes and weight loss may also protect the brain.
Learn How the MND Association is fighting MND
Read the new report from the MND Association – learn about their work on translational research, work funded, partnerships and about new trial designs.
Blood Test may improve Alzheimer’s diagnosis in primary care
Research reported at AAIC shows blood tests can be 90% accurate in diagnosing Alzheimer’s disease and could be use in primary care and memory clinics.
EU regulator rejects Lecanemab
The European Medicines Agency (EMA) has rejected a licence for Lecanemab – a drug shown to work on clearing amyloid plaques.
New Tool to Bridge Research and Health Policy
NIHRNew interactive map from University of Oxford and NIHR ARC OxTV empowers researchers to navigate complex UK health policy landscape
How are ECRs supported? Overview of global policy approaches
New paper published in Alzheimer’s & Dementia explores how Dementia ECRs are supported in G20 country goverment / charity dementia policies and plans.
How to prepare for the new NIH Simplified Review Framework
NIH blog flagging significant future adjustments on the horizon for NIH peer review for applications – ensure you’re on top of what’s to come
£1.5m for First National Dementia Inequalities Network
Dementia Researcher is pleased to be a partner in the new EquaDem £1.5m programme to establish first national dementia inequalities network.
UCL Movement Disorders Symposium
Catch-up on this Seminar and hear from international experts on recent discoveries and promising pathways to understand, monitor and treat movement disorders.
Donanemab approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s
With FDA Approval for Donanemab confirmed, it now has a new name…. welcome to Kisunla™ for the Treatment of Early Symptomatic Alzheimer’s Disease.
Revised criteria for diagnosis and staging of Alzheimer’s
Discover the latest updates in Alzheimer’s diagnosis & staging with revised criteria. Incorporating biomarkers, this framework bridges research & clinical care.